Navigation Links
Smith & Nephew CEO Interviewed on Q2 2011 Results
Date:8/5/2011

LONDON, August 5, 2011 /PRNewswire/ --

 

Medical devices group Smith & Nephew reports sales growth of 12% and underlying sales growth of 5%.

In an interview with financial broadcaster http://www.cantos.com, new CEO Olivier Bohuon talks Q2 results and introduces his plans for a new Strategic Framework that details efficiency plans and announces a new focus on emerging markets. 

Bohuon also announced plans to inject an additional $300m into R&D over the next five years, and to focus the business on performance, innovation and a more global presence.

The interview and transcript are available now on http://www.cantos.com/company/Smith%20and%20Nephew

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@cantos.com or phone +44-207-936-1352.


'/>"/>
SOURCE Smith & Nephew plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
2. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
3. Canadas Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
4. GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration
5. Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee
6. Academics Launch New Web Site Holding Jeffrey Smith's Claims on GM Foods Up to Peer-Reviewed Science
7. SpineSmith to Present at the 5th Annual Stem Cell Summit
8. SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement
9. ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales
10. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
11. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... focused to spot sizes smaller than half the wavelength ... beat this diffraction limit is based on optical antennas, ... They have the ability to concentrate (focus) light to ... magnitude smaller than what conventional lenses can achieve. Tiny ...
... As previously announced on October 24th, 2009 delSECUR CORPORATION ... its del-Id system to QTech Systems Inc. in an Asset ... that time and as mentioned in the Press Release on ... diligently on the del-Id prototype development for commercialization. ...
... Cellectis (Alternext: ALCLS), the genome engineering specialist, ... with a pharmaceutical company covering certain uses of its homologous ... field. This agreement has triggered an immediate payment ... of the arrangement have not been disclosed. ...
Cached Biology Technology:Transmission lines for nanofocusing of infrared light 2Transmission lines for nanofocusing of infrared light 3delSECUR CORPORATION Announces Its Dissolution; and the Distribution of Its Asset to Its Lenders and Shareholders of the Corporation 2
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... Down syndrome - or trisomy 21 - is the ... from a chromosomal abnormality where cells of affected individuals ... the human genome). A study conducted by Stylianos Antonarakis ... and Development at the University of Geneva (UNIGE) Faculty ... on how the extra chromosome 21 upsets the equilibrium ...
(Date:4/17/2014)... White House honored Clemson professor Rajendra Singh Thursday ... to promote and expand solar deployment in the ... D. Houser Banks Professor of Electrical and Computer ... Nanoelectronics, is considered a local hero leading the ... economic opportunity in solar power and driving policy ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... This release is available in German . ... against diseases. The early detection of pathogens and the subsequent ... a protective shield. However, the pathogens that cause plant diseases ... natural cell wall reaction in plants. "One particularly ingenious attacker, ...
... are translated into a perception by complex interactions of ... temporal organization of neuronal activity during decision-making and object ... Max Planck Institute for Biological Cybernetics in Tbingen, in ... Institute for Medical Research in Heidelberg, now investigated how ...
... WEST LAFAYETTE, Ind. - Purdue University biologists identified a new ... could provide a target for new antibiotics. Zhao-Qing Luo, ... said the team discovered a new enzyme used by the ... - to control its host cell in order to take ...
Cached Biology News:TUM researchers discover a new switch in resistance to plant diseases 2Deeper insight in the activity of cortical cells 2Deeper insight in the activity of cortical cells 3Purdue biologists identify new strategy used by bacteria during infection 2Purdue biologists identify new strategy used by bacteria during infection 3
... the cost-effective solution for entry level imaging ... research imaging tasks, MetaVue enables time lapse, ... analysis. Compatibility with MetaMorphs extensive and ... has the power to drive motorized microscopes, ...
... for microRNA expression profiling ,miRCURY ... Locked Nucleic Acid (LNA) technology to provide ... short microRNA (miRNA) targets. miRCURY LNA Arrays ... RNA (no need for microRNA enrichment) labeled ...
... XL extends the MSn performance of the ... tools to generate extensive structural information for ... , Multiple dissociation techniques (PQD, ETD, ... unpredicted metabolites , Fast polarity switching for ...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Biology Products: